Prospects of Drug Bioequivalence Studies in Pakistan

Authors

  • S Khaqan Hasan Director, Institute of Pharmaceutical and Environmental Research, Dow University of Health Sciences, Ojha Campus, Karachi, Pakistan.

Abstract

A patented drug becomes generic after losing patent protection and it is estimated that drugs worth US$ 75 billion would become unpatented in 2012 thus creating a huge market for generic drugs. The generic drugs can then be manufactured by any pharmaceutical firm other than the original patentee company and developing countries like India and China are manufacturing now any generic drugs. It is, however, necessary to prove that produced brand of the generic drug has the same quality, safety and efficacy as the original (originator’s/ comparator’s) drug by carrying out Bioavailability.

Downloads

Download data is not yet available.

References

Overview of the Indian CRO Market. (http://blogs. veedacr. com/List/Posts/Post.aspx?ID=335)

Pharma industry seeks government action against fake drugs. The Express Tribune February22, 2011 [Accessed January 04, 2013]. Available from: (http://tribune.com.pk /story/121892/pharma-industry-seeks-governmentaction-against-fake-drugs/).

Pharma exports to touch U.S. $ 600m by 2010: exporters. Daily times. Site Edition June 30, 2007 [Accessed January 04, 2013]. Available from: (http:// www.dailytimes.com.pk/default.asp?page =2007%5C06%5C30%5Cstory_30-6-2007_pg5_2)

Ponchagnula R, Agarwal S, Kaur KJ, Singh I, Kaul, CL. Evaluation of rifampicin bioequivalence in fixed dose combinations using the WHO/ IUATLD recommendation protocol Int. J Tuber Lung Dis 2000; 4: 1169-72.

World Health Organization: additional guidance for organizations performing in vivo bioequivalence studies. WHO technical Report service, No937, 2006. [Accessed March 31,2011] Available From: (http://apps.who.int/ prequal/info_general/documents/TRS937/

WHO_TRS_937__annex9_eng.pdf)

World Medical Association Declaration of Helsinki Ethical Principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly Helsinki Finland, June 1964 and amended by the 59th WMA General Assembly, Seoul, October 2008 Available from: http://www.wma.net/en/30pulications/10 policies/b3/17c.pdf

Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Geneva, World Health Organization, 1995 (WHO technical Services Report No.850): 90-137.

Good Laboratory Practices (GLP) Quality practices for regulated nonclinical research and development. Geneva/World Bank/WHO, Special Program for Research and Training in Tropical Disease (TDR), 2001.

International Conference on Harmonization (ICH) Guidelines. Tripartite Harmonization Guidelines for Good Clinical Practice, step 4, Geneva, ICH Secretariat (IFPMA), 1996. Available from: http://www.ich.org / fileadmin/Public_Web_Site/ICH_Products/Guidelines/

Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf

40% of all medicines in Pakistan are fake. Daily times, March 09, 2006. Available from: http://www.dailytimes. com.pk/default.asp?page=200639story_9-3-2006_pg7_60

Downloads

Published

2012-06-25

How to Cite

Hasan, S. K. . (2012). Prospects of Drug Bioequivalence Studies in Pakistan. Journal of the Dow University of Health Sciences (JDUHS), 6(2), 39–41. Retrieved from https://jduhs.com/index.php/jduhs/article/view/1497

Issue

Vol. 6 No. 2

Section

Editorial

License

Copyright (c) 2021 S Khaqan Hasan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal.